Edison Investment Research - K3 Business Technology Group (KBT) Flash note: UK visitor attraction software acquisition

Report

Edison Investment Research

Flash note: UK visitor attraction software acquisition

K3 continues to strengthen its position in the visitor attractions and leisure sector with the acquisition of Merac, a UK-based supplier of electronic PoS and management systems, for up to Â£1.45m in cash. The deal brings a roster of UK customers as well as adding to the companyâ€™s portfolio of own-IP solutions.

04/07/2016 2 EN

Underlying

K3 Business Technology Group

See profile

United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: FY16 trading in line

K3 expects to report FY16 results broadly in line with market expectations. Trading was encouraging during H216, with a good level of contract wins in the final months of the year. Net debt has reduced over the year, although is higher than we forecast, partly due to a major retail customer going into administration close to year-end. We make no changes to estimates, pending FY16 results on 13 September.

July 14, 2016 July 14, 2016 3 EN

Edison Investment Research

Update: Scandinavian retail software acquisition

K3 is acquiring DdD, a Danish point-of-sale (PoS) solution provider, for up to â‚¬10m/Â£7.9m. The company is raising Â£12.8m (net) from the issue of 4.1m shares to fund the deal and future product development. The acquisition adds proprietary retail software and should be complementary to K3â€™s existing retail software solutions. The deal also expands K3â€™s presence in Northern Europe and offers cross-selling potential.

April 26, 2016 April 26, 2016 5 EN

On the Beach Group - Feeling festive

The increase of 22% in booked total transaction value (TTV) both in H124 and for this summer, driven by successful expansion into premium and long haul and backed by its pioneering perks, confirm On the Beach’s (OTB’s) progress in addressing a market it estimates to be 5x more valuable than its core Value (3*) business (now just 25% of bookings) as well as more dynamic. Another ‘very big deal’ for OTB is its new ‘transformational’ partnership with Ryanair, its most significant low-cost carrier, ensuring free and fair access to seat supply and marking a more positive relationship, given outstan...

May 24, 2024 May 24, 2024 1 EN

Alison Turner

Alison Turner

Pan African Resources - An accounting storm in a legal teacup

This morning, Pan African announced that it may have been in technical breach of the net asset test when it paid out dividends to shareholders in the five years from FY19–23 and also when it instigated its share buyback programme in 2022. As attested to by the fact that it took five years to be noticed, the apparent breach arises from the nexus of an arcane bit of legislation and a curious distinction between the presentation currency of the group (the US dollar) and its functional currency (the South African rand) and the effect of the depreciation of the latter against the former on the dist...

May 24, 2024 May 24, 2024 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - All eyes on Q3 readout after Q1 update

Cereno Scientific’s Q124 results provided a financial update and recapped the company’s clinical plans and progress. The Phase II trial for lead asset CS1 (pulmonary arterial hypertension, PAH) remains on track for a Q324 readout and we expect the Expanded Access Program approved by the FDA in January 2024 will help Cereno build a more robust data package for the subsequent Phase IIb/III trial. Additionally, the clinical trial application (CTA) submission for CS014 to the EMA in April 2024 brings a second asset to the clinic, bolstering the company’s clinical pipeline. We believe Cereno’s liqu...

May 24, 2024 May 24, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Flash note: UK visitor attraction software acquisition

Update: FY16 trading in line

Update: Scandinavian retail software acquisition

On the Beach Group - Feeling festive

Pan African Resources - An accounting storm in a legal teacup

Cereno Scientific - All eyes on Q3 readout after Q1 update

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe